Literature DB >> 19596596

Endovascular aortic arch repair: hopes and certainties.

M Schoder1, J Lammer, M Czerny.   

Abstract

For aneurysms and dissections involving the aortic arch, the traditional treatment is open surgical repair requiring cardiopulmonary bypass and deep hypothermic circulatory arrest. Reported mortality rates range from 7% to 17% and neurologic injury rates range from 4% to 12%. Since the first clinical applications of endovascular repair in the early 1990s, this less-invasive treatment modality has evolved steadily. For the treatment of aortic arch pathologies, combined open and endovascular strategies (hybrid procedures) have gained a widespread implementation. Evidence to date proves the feasibility of open surgical branch re-vascularisation followed by endovascular repair into the proximal arch. For hybrid procedures, mortality and stroke rates are given as 0-20%, and 0-8%, respectively. Alternative approaches using fenestrated and branched stent grafts have been considered. Although this technique is challenging and devices are not available widely, it is anticipated that this new technique will expand the range of aortic arch pathologies that can be treated by endovascular means.

Entities:  

Mesh:

Year:  2009        PMID: 19596596     DOI: 10.1016/j.ejvs.2009.06.007

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  9 in total

1.  Hybrid procedure for thoracic aortic disease.

Authors:  Tucheng Sun; Gang Wang; Kailun Zhang; Huimin Liang; Xionggang Jiang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-11-10

2.  Aortic aneurysms and trans-apical endovascular repair in high risk heart transplant recipient, one year follow up.

Authors:  Khalil Ahmad; Kim Terp; Gratien Andersen; Vibeke Hjortdal
Journal:  J Thorac Dis       Date:  2015-11       Impact factor: 2.895

Review 3.  Minimally Invasive Techniques for Total Aortic Arch Reconstruction.

Authors:  Jason Faulds; Harleen K Sandhu; Anthony L Estrera; Hazim J Safi
Journal:  Methodist Debakey Cardiovasc J       Date:  2016 Jan-Mar

4.  One-stage hybrid procedure without sternotomy for treating thoracic aortic pathologies that involve distal aortic arch: a single-center preliminary study.

Authors:  Changwei Ren; Xi Guo; Lizhong Sun; Lianjun Huang; Yongqiang Lai; Shangdong Xu
Journal:  J Thorac Dis       Date:  2015-05       Impact factor: 2.895

5.  Application of triple-chimney technique using C-TAG and Viabahn or Excluder iliac extension in TEVAR treatment of aortic arch dilation diseases.

Authors:  Lixin Wang; Yulong Huang; Daqiao Guo; Xin Xu; Bin Chen; Junhao Jiang; Jue Yang; Zhenyu Shi; Ting Zhu; Zhihui Dong; Yun Shi; Xiao Tang; Jianing Yue; Xiang Hong; Gang Chen; Yihui Chen; Xiushi Zhou; Weiguo Fu; Yuqi Wang
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

6.  Hybrid endovascular repair in aortic arch pathologies: a retrospective study.

Authors:  Xiaohui Ma; Wei Guo; Xiaoping Liu; Tai Yin; Xin Jia; Jiang Xiong; Hongpeng Zhang; Lijun Wang
Journal:  Int J Mol Sci       Date:  2010-11-18       Impact factor: 5.923

7.  Hybrid treatment of aortic arch disease.

Authors:  Patrick Bastos Metzger; Fabio Henrique Rossi; Samuel Martins Moreira; Mario Issa; Nilo Mitsuru Izukawa; Jarbas J Dinkhuysen; Domingos Spina Neto; Antônio Massamitsu Kambara
Journal:  Rev Bras Cir Cardiovasc       Date:  2014 Oct-Dec

8.  The chimney technique for preserving the left subclavian artery in thoracic endovascular aortic repair.

Authors:  Yuguo Xue; Lizhong Sun; Jun Zheng; Xiaoyong Huang; Xi Guo; Tiezheng Li; Lianjun Huang
Journal:  Eur J Cardiothorac Surg       Date:  2014-07-09       Impact factor: 4.191

9.  Endovascular Stent-Graft Repair of the Ascending Aorta: Assessment of a Specific Novel Stent-Graft Design in Phantom, Cadaveric, and Clinical Application.

Authors:  Sven R Hauck; Alexander Kupferthaler; Marlies Stelzmüller; Wolf Eilenberg; Marek Ehrlich; Christoph Neumayer; Florian Wolf; Christian Loewe; Martin A Funovics
Journal:  Cardiovasc Intervent Radiol       Date:  2021-06-27       Impact factor: 2.740

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.